English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduUC Davis Health physicians have performed the first single anesthesia diagnosis to treatment of lung cancer utilizing a fully robotic approach in the UC Health System. Procedure allows physicians to diagnose and remove lung cancer mass during single surgery.
Tag: Lung Cancer
MD Anderson Research Highlights for May 4, 2022
Featured studies include clinical advances with a new combination therapy targeting angiogenesis in platinum-resistant ovarian cancer and a promising immunotherapy combination for kidney cancer, plus laboratory studies that focus on targeting ferroptosis in specific lung cancers, developing chimeric antigen receptor (CAR) T cell therapies for blastic plasmacytoid dendritic cell neoplasms, and characterizing racial and ethnic disparities in breast cancer early detection.
Moffitt Researchers Develop Model to Predict Patients with Poor Lung Cancer Outcomes
Moffitt Cancer Center researchers are working to improve the ability to identify patients who are at a higher risk of poor survival through radiomics, an area of science that uses imaging, such as CT scans and MRIs, to uncover tumoral patterns and characteristics that may not be easy to spot by the naked eye. Results of their newest study was published today in Cancer Biomarkers.
How air pollution alters lung tissue, increasing cancer susceptibility
Scientists have identified a mechanism that explains how fine air pollution particles might cause lung cancer, according to a study published today in eLife.
Simple changes in care reduced heart exposure during lung cancer radiation treatment
A team at the University of Michigan Health Rogel Cancer Center, in partnership with the statewide Michigan Radiation Oncology Quality Consortium (MROQC) lung cancer collaborative, found that raising awareness about the risk of radiation exposure to the heart and standardizing cardiac exposure limits reduced the average dose to the heart by 15% and reduced the number of patients receiving the highest heart doses by half without minimizing tumor treatment or increasing dosage to other at-risk organs in the chest
NCCN Announces Funding for Early-Stage Non-Small Cell Lung Cancer Projects, in Collaboration with AstraZeneca
The National Comprehensive Cancer Network’s Oncology Research Program to oversee projects focused on improving patient care and outcomes in early-stage non-small cell lung cancer in collaboration with AstraZeneca.
Confronting Disparities in Lung Cancer
Compared with all other racial and ethnic groups in the United States, Black people are disproportionally more affected by lung cancer. Sharon R. Pine, PhD, a resident member of Rutgers Cancer Institute of New Jersey, associate professor of Pharmacology and Medicine at Rutgers Robert Wood Johnson Medical School and member of the Cancer Health Equity Center of Excellence e, discusses the barriers that Black people face, the research being done on racial health disparities and how action can be taken now.
MD Anderson Research Highlights for November 3, 2021
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include the cost-effectiveness of expanded lung cancer screening criteria, a novel biomarker for predicting immunotherapy responses, development of a technique for multiplex single-cell chromatin profiling, combination immunotherapy for bone metastatic prostate cancer, understanding drivers of lung cancer metastasis, and enabling new T cell therapies for treating COVID-19.
The Society of Thoracic Surgeons and AstraZeneca Join Forces to Accelerate Lung Cancer and Disparities Research, Education
The Society of Thoracic Surgeons (STS) has entered into a partnership with biopharmaceutical company AstraZeneca in an effort to advance and improve lung cancer treatment and eliminate disparities in health care.
ASTRO 2021: New Study from Memorial Sloan Kettering Finds Targeted Radiation Beneficial in Cases of Advanced Lung Cancer
A new study from Memorial Sloan Kettering Cancer Center found that high-dose radiation therapy administered alongside systemic therapy in patients with metastatic non-small cell lung cancer can help extend progression free survival. This is the first and largest randomized clinical trial ever to study the use of stereotactic body radiation therapy (SBRT) in treating oligoprogressive metastatic lung and breast cancers. These findings will be presented during this year’s American Society for Radiation Oncology (ASTRO) meeting in Chicago.
Intervention eliminates Black-white gaps in survival from early-stage breast and lung cancer
A new study shows that system-level changes to the way cancer care is delivered can also eliminate Black-white disparities in survival from early-stage lung and breast cancer. By identifying and addressing obstacles that kept patients from finishing radiation treatments for cancer, the intervention improved five-year survival rates for all patients and erased the survival gap between Black and white patients. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
High-dose radiation thwarts tumor growth in patients with advanced lung cancer
High-dose radiation therapy can be used to lengthen progression-free survival for people with advanced lung cancer when systemic therapy has not fully halted the growth or spread of metastases, according to a new study. Findings will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Virtual lung cancer screening is just as effective as in-person screening
A novel telemedicine lung cancer screening effort during the COVID-19 pandemic shows that virtual single-visit screenings are just as effective as single-visit screenings done in person at the hospital.
NCCN Publishes New Guide to Improving Knowledge and Quality of Life for Small Cell Lung Cancer Patients
NCCN announces the publication of new NCCN Guidelines for Patients®: Small Cell Lung Cancer (SCLC), which is a neuroendocrine tumor type of lung cancer that is linked to smoking and tends to be aggressive. This guide is free to view or download at NCCN.org/patientguidelines and is funded by NCCN Foundation®.
New study shows that different types of cancers are likely to spread to specific areas of the brain
Brain metastasis occurs when cancer in one part of the body spreads to the brain. The lifetime incidence of such metastatic brain tumors in cancer patients is between 20%-45%, research shows.
Antibody-drug conjugate shows impressive activity in patients with non-small cell lung cancer with mutation in HER2 gene
More than half of patients with non-small cell lung cancer (NSCLC) bearing a mutation in the HER2 gene had their tumors stop growing or shrink for an extended time after treatment with a drug that hitches a chemotherapy agent to a highly targeted antibody, an international clinical trial led by investigators at Dana-Farber Cancer Institute has found.
Right Program Could Turn Immune Cells into Cancer Killers
Cancer-fighting immune cells in patients with lung cancer whose tumors do not respond to immunotherapies appear to be running on a different “program” that makes them less effective than immune cells in patients whose cancers respond to these immune treatments, suggests a new study led by researchers at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy.
Yale Cancer Center Study Shows Stem-Like T Cells Could Aid Immunotherapy in Cancer Treatment
In a new study by Yale Cancer Center, researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters.
New Chief of Thoracic and Head and Neck Medical Oncology Named to New Jersey’s Only NCI-designated Comprehensive Cancer Center
Expanding its multidisciplinary teams of highly specialized experts uniquely focused on the management of head and neck cancers and cancer of the lung, pleura and mediastinum, Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have welcomed Missak Haigentz, Jr., MD, as chief of Thoracic and Head and Neck Medical Oncology and clinical director for Oncology Integration.
Researcher receives $2.5 million grant to develop lung cancer treatment
A researcher at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center received a five-year, $2.5 million grant from the National Cancer Institute to develop a novel therapy to treat lung cancer.
Novel AI Blood Testing Technology Can ID Lung Cancers with High Accuracy
A novel artificial intelligence blood testing technology developed by researchers at the Johns Hopkins Kimmel Cancer Center was found to detect over 90% of lung cancers in samples from nearly 800 individuals with and without cancer.
Adoptive Cell Therapy Plus Checkpoint Inhibitors Show Promise in Non-Small Cell Lung Cancer
Researchers in Moffitt Cancer Center’s Lung Cancer Center of Excellence believe a combination of checkpoint inhibitors with adoptive cell therapy could be the answer for non-small cell lung cancer patients. Results of their investigator-initiated phase 1 clinical trial evaluating the checkpoint inhibitor nivolumab in combination with tumor infiltrating lymphocyte (TIL) therapy was published today in Nature Medicine.
Yale Cancer Center Perspective Highlights New Advances for NSCLC
A new publication by Yale Cancer Center highlights recent breakthrough therapies developed to treat non-small cell lung cancer (NSCLC). The goal of the study is to provide views on how basic science advances will impact clinical research areas to help influence how NSCLC will be managed over the coming decade.
MD Anderson Research Highlights for August 11, 2021
Current advances include insights into anti-tumor responses, a targeted therapy combination for biliary tract cancers, biomarkers that may predict response to DNA damage repair inhibitors, a “virtual biopsy” using artificial intelligence to characterize tumors, new targeted and immunotherapy approaches for pancreatic cancer, understanding the impact of TP53 mutations on acute myeloid leukemia treatments, as well as a new strategy to overcome treatment-resistant KRAS-mutant lung cancer.
Virtual Lung Cancer Screenings Offered by Hackensack Meridian Hackensack University Medical Center
Telehealth Visits Provide Early Detection, More Treatment Options and Better Chance of Survival August 1 is World Lung Cancer Awareness Day, a global initiative to raise awareness to the fact that lung cancer is the most common cause of cancer…
Mayo Clinic study suggests patients with lung cancer be screened for MET oncogene
Research by investigators at Mayo Clinic Cancer Center suggests that physicians should screen patients with lung cancer for MET amplification/overexpression before determining a treatment strategy. Their findings are published Cancer Discovery, a journal of the American Association for Cancer Research.
Moffitt Receives $10.2 Million Grant to Develop New Lung Cancer Therapies
The National Cancer Institute has awarded the Lung Cancer Metabolism Working Group at Moffitt Cancer Center with a Research Program Project Grant (P01CA250984). The grant, which will provide more than $10.2 million over five years, will support team research with a focus on investigating lung cancer metabolism.
New research uncovers how cancers with common gene mutation develop resistance to targeted drugs
A new study by Dana-Farber Cancer Institute researchers has given scientists their first look at the genomic landscape of tumors that have grown resistant to drugs targeting the abnormal KRASG12C protein. Their work shows that, far from adopting a common route to becoming resistant, the cells take a strikingly diverse set of avenues, often several at a time. The findings, reported online today in the New England Journal of Medicine, underscore the need for new drugs that inhibit KRAS differently than current agents do.
New study to reveal health equity impacts of flavored tobacco bans
A new University of Kentucky College of Medicine study will examine how policies that restrict the sale of flavored tobacco products including menthol cigarettes impact health disparities among vulnerable populations.
Early Lung Cancer Coopts Immune Cell Into Helping Tumors Invade the Lungs, Mount Sinai Researchers Discover
Immune cells that normally repair tissues in the body can be fooled by tumors when cancer starts forming in the lungs and instead help the tumor become invasive, according to a surprising discovery reported by Mount Sinai scientists in Nature in June.
Targeted Therapy Pralsetinib Safely and Effectively Treats Lung and Thyroid Cancers with RET Alterations
Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancer.
NUS researchers develop world’s first blood test for real-time monitoring of cancer treatment success
A team of researchers from the NUS Department of Biomedical Engineering and Institute for Health Innovation & Technology has developed a novel blood test called ExoSCOPE that could tell doctors whether cancer treatment is working for a patient, within 24 hours after the treatment. This will enable doctors to customise the treatment plan to improve patients’ chances of recovery.
Newly approved targeted therapy sotorasib prolongs survival in KRAS G12C-mutated lung cancer
Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer, according to researchers from The University of Texas MD Anderson Cancer Center.
Newly approved drug effective against lung cancer caused by genetic mutation
The new drug sotorasib reduces tumor size and shows promise in improving survival among patients with lung tumors caused by a specific DNA mutation, according to results of a global phase 2 clinical trial led by Washington University School of Medicine in St. Louis. The drug is designed to shut down the effects of the mutation, which is found in about 13% of patients with lung adenocarcinoma, a common type of non-small-cell lung cancer.
Inflammation and Procalcitonin Predict Success, or Not, of Lung Cancer Treatment
In patients with non-small cell Lung Cancer (NSCLC), the presence of either high chronic inflammation, or procalcitonin levels in the blood as a response to bacterial infection, both predict a poor response to treatment with immune checkpoint blockade.
Delaying lung cancer surgery associated with higher risk of recurrence, death
New research from Washington University School of Medicine in St. Louis has found that postponing lung cancer surgery for more than 12 weeks from the date of diagnosis with a CT scan is associated with a higher risk of recurrence and death.
University Hospitals First in Northeast Ohio to Use New Technology for Lung Cancer Diagnosis
A new innovation that holds promise to fight lung cancer is now in use at University Hospitals Cleveland Medical Center.
Cleveland Clinic experts available to comment on cancer research presented at ASCO Annual Meeting
Cleveland Clinic cancer researchers are involved with more than 50 studies that’ll be presented at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting, June 4—8, 2021. Key research from Cleveland Clinic focuses on advancements in the prevention and…
Metabolic inhibitor IACS-6274 shows early antitumor effects in underserved patients with advanced cancers
A metabolic inhibitor drug, IACS-6274, developed by MD Anderson’s Therapeutics Discovery division, is well-tolerated and showed early signs of anti-tumor activity in a Phase I trial being presented at the 2021 ASCO Annual Meeting.
Memorial Sloan Kettering Announces New Initiative to Focus on Lung Cancer Research
Memorial Sloan Kettering Cancer Center (MSK) today announced a $20 million gift from the Ge Li & Ning Zhao Family Foundation to support lung cancer research and the development of new therapies to treat this disease.
Bringing medical AI closer to reality
For AI to continue to transform cancer diagnoses, researchers will have to prove that the success of their machine-learning tools can be reproduced from site to site and among different patient populations. Biomedical engineering researchers at Case Western Reserve University say they doing just that. They say they have demonstrated that their novel algorithms for distinguishing between benign and malignant lung cancer nodules on CT scan images from one site can now be successfully reproduced with patients from other sites and locations.
Virtual Lung Cancer Screenings Being Offered by Hackensack Meridian Health
Telehealth Visits Provide Early Detection, More Treatment Options and Better Chance of Survival
Researchers identify potential combination therapy for aggressive lung cancer
The combination approach uses immune checkpoint inhibitors with ATRA, a safe medication that is widely used to treat leukemia.
MD Anderson and Boehringer Ingelheim expand collaboration to accelerate development of KRAS and TRAILR2 compounds in lung cancer
MD Anderson and Boehringer Ingelheim have expanded their joint Virtual Research and Development Center to accelerate the development of new targeted therapies against KRAS and TRAILR2 in lung cancer.
Case Western Reserve awarded $3 million National Cancer Institute grant to apply AI to immunotherapy in lung cancer patients
Medical researchers from Case Western Reserve University, New York University (NYU), and University Hospitals have been awarded a five-year, $3 million National Cancer Institute grant to develop and apply artificial intelligence (AI) tools for predicting which lung cancer patients will respond to immunotherapy.
CAP Opens PD-L1 Lung Tumor Testing Guideline for Public Comment
The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients with non-small cell lung cancer (NSCLC) who are being considered for immunooncology therapy.
Starting Smoking Cessation in Hospitalized Patients Would Reduce Many Premature Deaths
Each year in the U.S., about 30 million hospitalizations occur in individuals 18 and older. Of these, more than 7 million are current cigarette smokers whose average hospital stay is several days. Researchers say that starting smoking cessation therapy during hospitalization and maintaining high adherence post-discharge can markedly improve permanent quit rates in these patients with minimal to no side effects. Cessation therapy also should include long-term counseling and at least 90 days of a prescription drug, specifically, varenicline.
Physician and Patient Groups Call On CMS to Update Medicare Lung Cancer Screening Coverage
STS—in collaboration with the GO2 Foundation for Lung Cancer and the American College of Radiology—formally requested that CMS update its coverage policies to reflect the new USPSTF lung cancer screening guidelines.
Study finds high tumor mutation burden predicts immunotherapy response in some, but not all, cancers
A high rate of genetic mutations within a tumor, known as high tumor mutation burden, was only useful for predicting immunotherapy responses in a subset of cancer types, suggesting that this may not reliably be used as a universal biomarker.
Cancer physician-scientist offers expertise on new lung cancer CT screening recommendations
Nasser Hanna, M.D., can provide expertise on the new guidelines for lung cancer screening recently issued by the U.S. Preventive Service Task Force. The USPSTF recommends yearly low-dose CT screening for those who are at high risk of developing lung…